{"id":"W3171042793","doi":"10.1016/j.ctarc.2021.100405","title":"Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Cilag; Takeda Oncology; Chugai Pharmaceutical; Genentech; Aptitude Health; Sierra Oncology; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Oryzon Genomics; Astellas Pharma; Eisai; MacroGenics; Mersana Therapeutics; Agios Pharmaceuticals; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Array BioPharma; Daiichi Sankyo Europe; Servier; Gilead Sciences; Glenmark Pharmaceuticals; AbbVie; Exelixis; Sanofi; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; EUSA Pharma; AstraZeneca; Argenx; American Society of Clinical Oncology; GlaxoSmithKline; Amgen; LAM Therapeutics; Celgene","keywords":"Tolerability; Medicine; Internal medicine; Adverse effect; Lung cancer; Oncology; Pharmacokinetics; Pleural effusion; Clinical trial; Gastroenterology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001490072,0.0003247215,0.0008650759,0.0002454212,0.0002634947,0.0007579672,0.0003523926,0.0004861801,0.0005880859],"category_scores_gemma":[0.002431808,0.0002655484,0.0005273123,0.0002808965,0.0004339601,0.0005671962,0.0002024975,0.001099295,0.0003178937],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008037987,"about_ca_system_score_gemma":0.0006718174,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006131092,"about_ca_topic_score_gemma":0.001041573,"domain_scores_codex":[0.9992449,0.000347249,0.00003706197,0.0001432959,0.0001485642,0.00007897864],"domain_scores_gemma":[0.9989329,0.0002892567,0.0003701909,0.00007678734,0.00006336862,0.0002674451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2658861,0.007397161,0.2693372,0.0004567405,0.001333691,0.001863156,0.0008543678,0.009807106,0.1642263,0.0002785289,0.002338717,0.2762208],"study_design_scores_gemma":[0.02961476,0.2627601,0.6445775,0.00008579104,0.001366923,0.004467581,0.00029489,0.0139715,0.03471002,0.0002834034,0.007794364,0.00007318535],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997371,0.001464122,0.0002609106,0.00007887121,0.00001123997,0.00008316561,0.00008364556,0.00002655173,0.0006204619],"genre_scores_gemma":[0.999279,0.0001452783,0.0001799388,0.00006229922,0.00002088961,0.00003068837,0.0001405049,0.000005177932,0.0001362266],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001490072,"threshold_uncertainty_score":0.00788033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06452351404831635,"score_gpt":0.4140582255718726,"score_spread":0.3495347115235562,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}